NICE has published guidance (TA240) stating that it is unable to recommend the use of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer because no evidence submission was received from the manufacturer or sponsor of the technology.

This appraisal relates to the treatment of wild-type KRAS metastatic colorectal cancer for first-line treatment in combination with FOLFOX, and for second-line treatment in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).